Janssen-Cilag International NV (Janssen) Submits European Marketing Authorisation Application for Investigational Multi-

1. Andries et al. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis Science 14 January 2005: Vol. 307. no. 5707, pp. 223 - 227.

2. World Health Organization. TB Factsheet. March 2012. Available at: http://www.who.int/mediacentre/factsheet.... Accessed 16 August 2012.

3. World Health Organization, "Global TB Fact Sheet," 2011-2012. Available at: http://www.who.int/tb/publications/2011/.... Accessed 16 August 2012.

4. TB Europe Coalition, "TB in Europe," 2011. Available at http://www.tbcoalition.eu/what-is-tuberculosis/tb-in-europe. Accessed 16 August 2012.

5. McNeeley DF. Diacon H, Pym A, et al. TMC-207 versus placebo plus OBT for the treatment of MDR-TB: a prospective clinical trial. Oral presentation at the 41st Union World Conference on Lung Health; November 11-15, 2010; Berlin, Germany. Available at: http://uwclh.conference2web.com/content/.... Accessed 16 August.

6. Diacon et al. The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis, in The New England Journal of Medicine, vol. 360 no. 23, June 4, 2009.

7. 42nd Union World Conference on Lung Health in Lille, France, 46. Clinical trials of new drugs and regimens for MDR- and XDR-TB, October 30, 2011. Available at: http://www.worldlunghealth.org/confLille... . Accessed on 16 August 2012.

CONTACT: MEDIA CONTACT: Daniel De Schryver, +49-173-7689-149 , RuthWheatley, +44-7792-242-741; INVESTOR RELATIONS: Louise Mehrotra / StanPanasewicz, +1-732-524-6491 / +1-732-524-2524